JPRN-jRCTs031180440已完成未知
Multicenter trial of effects for glucometabolism, platelet activation marker and inflammatory marker by single or combination therapy with tofogliflozin and anagliptin in type 2 diabetic patients
omura Shosaku0 个研究点目标入组 50 人开始时间: 2019年3月27日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
Comparisons between group showed no significant differences in many parameters. On the other hand, Comparison within groups at 0 and 48 weeks showed significant changes in many parameters.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 94age old（—）
- 性别
- All
入选标准
- •1.under treatment by once dialy type DPP-4 inhibitor
- •2.7.0% < HbA1c < 9.0%
- •3.BMI > 18.0 kg/m2
- •4.20 years < age < 95 years
- •5.written informed concent
排除标准
- •1.type 1 diabetes or secondary diabetes
- •2.contraindication for medicine
- •4.Use of twice daily type DPP-4 inhibitor, or weekly type DPP-4 inhibitor, or DPP-4 inhibitor related combination drug, or SGLT2 inhibitor, or GLP-1 receptor agonist within 4 weeks.
- •5.eGFR < 30mL/min/1.73m2
- •6.AST or ALT > 120IU/L
- •7.history of appoplexy
- •8.pregnancy or lactationperiod
- •9.urinary infection, social disease
- •10.malignancy
- •11.inappropriate patients
研究者
相似试验
尚未招募
不适用
Multicenter trial of effects for glucometabolism, platelet activation marker and inflammatory marker by single or combinathin therapy with tofogliflozin and anagliptin in type 2 diabetic patientstype 2 diabetes mellitusJPRN-UMIN000028634Kansai Medical University100
已完成
Unknown
Study on the glucose-lowering effect and metabolic benefit of SGLT2 inhibitorsDiabetes mellitusJPRN-UMIN000052955Department of Internal Medicine, Kurume University School of Medicine17
已完成
不适用
Comparative study about the effectiveness and the safety of atorvastatin original drug and generic drug.DyslipidemiaJPRN-UMIN000034049Kanagawa Association of Medical and Dental Practitioners42
已完成
2 期
Effect of active ergonomic workstation on official personnelSitting behavior in office workers.-IRCT2016111122071N2Shiraz University of Medical Sciences45
已完成
3 期
Study investigating PK, PD, efficacy, safety, and immunogenicity of biosimilar denosumab (GP2411) in patients with postmenopausal osteoporosis.Postmenopausal OsteoporosisJPRN-jRCT2080224911Sandoz Inc.46